ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
WINSTON-SALEM, N.C., June 11, 2024 -- ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an...